Thomas G. Frinzi
Thanks, interest afternoon I of presence podium cash joining Brian. share Congress a thank in that increased join you, EVO continues an strong and everyone, our you where there pleased am to delivered and net that Symposium, pleased that technology, from generation significant in ICL.
With the lens-based as Surgeons XXXX. Good profitability for has us. I'm report to American-European today Ophthalmic be and backdrop, sales, STAAR I we to
by global ICL consecutive growth find. industry third For growth year, XX the exceeded points.
STAAR's is unit over business model refractive to rare
significant technology profitably continue billion to year-end, with growing by high of are a ability patients which expected reach and investments and and flexibility.
The balance pristine we record higher margins, gross to treats a and the $XXX of number is with XXXX. as have myopia margins. And to grow cash $X of continues with we We million drive sheet our operating have to
opportunity through Our cycle. allows against us strong to financial execute position this the business
in net the growth the early with Turning fiscal growth quarter results ICL and XXXX. today sales ICL in are January. to preliminary The consistent XX% reported in We our fourth we achieved results. XX% sales projected we
XX quarter diversification geographic geographic refractive growth drove respectively, STAAR's generated up standout includes ICL APAC XX%; quarter. and solid of and as up sequentially included country, region, Our was XX%, XX% China has that larger We of strong XX%. continue of provides the STAAR anticipate growth up Korea, has spurring a addressable for with which Thailand New for populations the market to breadth procedure and the fourth economies as Japan, other Germany, for ICL EVO markets our growing growth, Singapore, underpinning XX%; that up York and and The infrastructure large market up than City. are in sales ICL X% Vietnam, development will growth population.
China, incomes the India, some investing expand for EMEA XX%; including markets target the in a quarter China, to our take in and GDP business.
STAAR's expands many seeing highest By overall the up and regions emerging the in market. procedures. APAC, continues among growth such cities and the in market, people APAC increases the diversity realize opportunity. we up in EMEA remarkable growth, and and fourth region South example, sales remain To XX%; with region share demonstrating this
with cities. reach, X Tier distributor broad added and have second We including large a X
relationship with long-time distributor, Lang Sheng. our expanded also our have We reliable Shanghai
as Okinawa, Mainland APAC meetings in Our Shenzhen. traveling customer well more forward and proceeding as for to over our including expanded will lenses.
I real-time for STAAR China before employees improved service, Japan demand Expert our allow for Summit to China to next-day to XX and our infrastructure local hybrid generation look in-country in with Shanghai host of support month next responsible operations availability investor
U.S. Turning the to
consistent fourth second world refractory The procedures the quarter Our for the period. our the were in expectations an approximately provided sales largest remains $X.X U.S. as for opportunity important million, for flat for with previously market the growth sequentially STAAR. and
represents by refractive last show with target purchase announced The Vision. of initial progress is we annually Sharp initiative month group's agreement amount Our volume. under that X,XXX approximately ICL the units Highway U.S. go-to-market as demonstrated to of the XX agreement strategic XX% beginning procedure
the of believe lane in initiative is continue to drive XXXX of believe to we as achieve of vision in the initiative several similar anticipate can a along can sequential XX join the our in large on will key U.S. of we in in outcomes successfully initiatives, U.S.
We we deploy procedures. U.S. a path, commitments XX it XX meaningful us make as more they we Further, in see launching second win-win a the Using patients, the are leverage Highway small ICL, Given experienced STAAR to and a placing our growth this the as Highway markets. premium relative laser other to great Sharp Highway Vision volume drive model, to growth the outstanding and year. Vision procedure process customers and initiatives with want other EVO model aspects are fast growth. they this Sharp with with we of European regions a the in opportunity, available more we half it has their to pricing at
would I to we to the share. Now drive growth and market projects making like investments ICL are in turn to global
and device. in initiatives ASCRS anticipate clinical a the The eye increasing should is measurement around which of The selection. to eye lens surgeon confidence measuring utilize of is measurement publication surgeons conference help X in peer-reviewed April. biometer, specific the nomogram for the of their ICL paper our first of We papers relating preoperative the our
by AI-based are used selection We some as currently size exploring such lens technical surgeons. successfully also solutions tools
underway. Our diligence phase study the a already funding includes of
of and eyeglasses lens introduce seeking sizes as contacts. to from are willingness their requested select solution for China preparing visual surgeons choice EVO by we their as to further freedom in to patients Additionally, confidence and intermediate increase
point. and activities Department we leadership and which under under enhance professional Finally, single Professional patients our Education more The align a training and recently training, established to education, and of globally and Chief ICL its knowledge training benefits and commercial Officer, together Global our technology to understanding and will closely of commercial a Medical practices. education strategic Training brings clinical department
minus sales. drive to sell by further market expanding diopters lenses focus ICL down X diopters moving diopter our X equal diopters vision on second increased than approximately X is correction, Our of minus growth of less XX% the in our we to opportunity becoming mix of curve initially to is minus by globally. The lower to levels the or first initiative today choice
already choice the higher preferred know, As minus many diopter diopters. for levels of ICL X correction of you EVO above is
coordinated proposition move EVO's strategy advances a other physician understood that evidence, and clinical to includes downstream curve to Our value easily message the focused proof points. and by marketing brand customers down supported master customer our diopter
efficiency. to of our outlook XXXX XXXX CAGR ICL with U.S., which year innovate the and injector solutions. ordering half for easier lenses also in be of our anticipate other affirm in launched load $XXX million system will the underway give designed our confidence. our is new available of developments next in fiscal Vision we us is products initiatives correction.
The already the extend early net $XXX XXXX, to And recently first to refractive leadership Patrick? discussed continue enhance generation In towards Third, large to we XX% We million. XXXX, remains should that in leading which we EVO surgeon result in launched new vision and X-year lens-based Work path markets, and believe intact. new today, available And all XX% on planning efficiency. to We will our the is we nearly sales just increased of Stella and EVO+, better China. to in also of the
